disclosed are syntheses of 11 β - hsd1 inhibitors and corresponding intermediates that are promising for the treatment of a variety of disease states including diabetes , metabolic syndrome , obesity , glucose intolerance , insulin resistance , hyperglycemia , hypertension , hypertension - related cardiovascular disorders , hyperlipidemia , deleterious gluco - corticoid effects on neuronal function , elevated intra - ocular pressure , various forms of bone disease , tuberculosis , leprosy , psoriasis , and impaired wound healing .